Webb7 maj 2024 · This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with prostate-specific membrane antigen (PSMA)-avid metastatic castration resistant prostate cancer … Webbcompany of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)
Lantheus to buy Progenics to chase both cancer imaging …
Webb2 okt. 2024 · Progenics is being delisted. About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc. Lantheus Holdings, Inc. is the parent company of LMI, a global … WebbOn February 20, Lantheus Holdings, Inc. (Nasdaq: LNTH) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced an Amended and Restated Agreement and Plan of Merger, whereby Progenics shareholders will receive, for each share of Progenics common stock held at the time of the closing of the merger, 0.31 of a share … rebels showcase 2023
Lantheus and Progenics Agree to Amended Transaction Terms …
Webb22 juni 2024 · Upon completion of the merger, Progenics stockholders received, for each share of Progenics common stock, 0.31 of a share of Lantheus common stock and … Webb29 mars 2024 · Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an … WebbLNTH-1095 (also known as MIP-1095) is a small molecule PSMA-targeted 131 I-based radioligand therapy for the treatment of metastatic castration-resistant prostate cancer … university of penn basketball